12.61

3.59% -0.47

After Hours: 12.64 0.03 +0.24%

Corvus Pharmaceuticals Inc (CRVS)

Overview News Price History Option Chain Financials Discussions Forecast

Corvus Pharmaceuticals Inc stock is traded at $12.61, with a volume of 1.18M. It is down -3.59% in the last 24 hours and down -29.36% over the past month. Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Previous Close:

$13.08

Open:

$12.81

24h Volume:

1.18M

Relative Volume:

0.83

Market Cap:

$1.06B

Revenue:

Net Income/Loss:

$-15.28M

P/E Ratio:

-24.92

EPS:

-0.5061

Net Cash Flow:

$-32.97M

1W Performance:

+2.44%

1M Performance:

-29.36%

6M Performance:

+47.14%

1Y Performance:

+263.40%

1-Day Range:

$12.58

$13.44

1-Week Range:

$11.42

$13.44

52-Week Range:

$3.38

$26.95

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name

Corvus Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(650) 900-4520

Address

901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

CRVS's Discussions on Twitter

Compare CRVS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVS Corvus Pharmaceuticals Inc	12.61	1.10B	0	-15.28M	-32.97M	-0.5061
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-26	Initiated	Goldman	Buy
Oct-13-25	Initiated	Barclays	Overweight
Jan-02-25	Initiated	H.C. Wainwright	Buy
Aug-18-23	Initiated	Oppenheimer	Outperform
Dec-01-21	Resumed	Jefferies	Buy
May-27-21	Initiated	Cantor Fitzgerald	Overweight
Feb-10-21	Downgrade	Mizuho	Buy → Neutral
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Credit Suisse	Outperform
Apr-18-16	Initiated	Guggenheim	Buy

View All

Corvus Pharmaceuticals Inc Stock (CRVS) Latest News

May 21, 2026

Corvus drops after early-stage trial data for eczema therapy - MSN

May 21, 2026

May 20, 2026

Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang

May 20, 2026

Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan

May 20, 2026

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com

May 20, 2026

Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan

May 20, 2026

Why Corvus Pharmaceuticals (CRVS) Is Down 28.0% After Rebound‑Free Soquelitinib Phase 1 Eczema Data And What's Next - Sahm

May 20, 2026

May 19, 2026

Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha

May 19, 2026

May 18, 2026